Danaher (DHR)

Healthcare · Diagnostics & Research · S&P 500
$215.61 -2.53% on the day Market cap $148.9B 52-week range $160.93 to $242.80 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
10% a year for 10 years

At a market value of $148.9B, Danaher's free cash flow of $5.3B (fiscal 2025) would need to grow about 10% a year for the stock to be worth today's price. That is close to what the company has delivered over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Danaher's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price9.5% a year
Free cash flow, last 9 years6.7% a year
Revenue, same period4.3% a year
Price to free cash flow28.3x

Fundamental grade

C

Five factors scored 1 to 9 from DHR's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation4
Profitability6
Growth6
Financial health5
Cash efficiency9

Key numbers

P/E (trailing)40.8x
P/E (forward)26.2x
Price / free cash flow28.3x
EV / EBITDA23.5x
Price / sales5.93x
Price / book2.97x
Revenue growth+5.5%
Operating margin20.4%
Net margin15.9%
Return on equity7.6%
Dividend yield0.64%
Debt / equity0.76x

Results from SEC filings

Fiscal years, from Danaher's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$24.8B$26.6B$23.9B$23.9B$24.6B
Net income$6.4B$7.2B$4.8B$3.9B$3.6B
Free cash flow$7.1B$7.4B$5.8B$5.3B$5.3B
EPS (diluted)$8.61$9.66$6.38$5.29$5.05
Operating margin25.7%28.3%21.8%20.4%19.1%

Where the revenue comes from

Revenue by segments, fiscal 2025.

Diagnostics$9.9B40%
Life Sciences$7.3B30%
Biotechnology$7.3B30%

Superinvestors who own DHR

From each investor's latest 13F filing (what a 13F shows).

None of the superinvestors we track held DHR in their latest 13F.

Insider buying

Open-market purchases by Danaher's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Mar 10, 2026 Ro Khanna
0$195.32—
Mar 10, 2026 Ro Khanna
0$195.32—
Nov 3, 2025 Ro Khanna
0$214.10—
Nov 3, 2025 Ro Khanna
0$214.10—
Oct 7, 2025 Julie Johnson
0$208.63—
Oct 7, 2025 Julie Johnson
0$208.63—

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when DHR trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Danaher's stock price imply?

At a market value of $148.9B, Danaher would need its free cash flow to grow about 10% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 7% a year.

Are Danaher insiders buying the stock?

6 open-market insider purchases of DHR in the last 12 months, from SEC Form 4 filings.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.